89BIO (ETNB) Competitors $14.78 -0.02 (-0.10%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETNB vs. RVMD, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, NUVL, and AXSMShould you be buying 89BIO stock or one of its competitors? The main competitors of 89BIO include Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. 89BIO vs. Its Competitors Revolution Medicines Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax CRISPR Therapeutics Nuvalent Axsome Therapeutics 89BIO (NASDAQ:ETNB) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Does the media prefer ETNB or RVMD? In the previous week, 89BIO and 89BIO both had 4 articles in the media. 89BIO's average media sentiment score of 0.72 beat Revolution Medicines' score of 0.50 indicating that 89BIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 89BIO 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of ETNB or RVMD? 94.3% of Revolution Medicines shares are held by institutional investors. 2.8% of 89BIO shares are held by company insiders. Comparatively, 8.2% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, ETNB or RVMD? 89BIO has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89BION/AN/A-$367.08M-$3.61-4.10Revolution Medicines$11.58M778.02-$600.09M-$4.50-10.71 Do analysts recommend ETNB or RVMD? 89BIO currently has a consensus target price of $25.81, suggesting a potential upside of 74.59%. Revolution Medicines has a consensus target price of $74.64, suggesting a potential upside of 54.87%. Given 89BIO's higher possible upside, analysts plainly believe 89BIO is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89BIO 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40Revolution Medicines 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93 Is ETNB or RVMD more profitable? Revolution Medicines' return on equity of -41.78% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets 89BION/A -94.48% -80.92% Revolution Medicines N/A -41.78%-35.63% Which has more volatility and risk, ETNB or RVMD? 89BIO has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. SummaryRevolution Medicines beats 89BIO on 7 of the 12 factors compared between the two stocks. Get 89BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.19B$3.35B$6.02B$10.34BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-4.1022.0184.7826.75Price / SalesN/A471.83598.92130.97Price / CashN/A44.9825.7730.18Price / Book4.4310.3212.476.64Net Income-$367.08M-$52.47M$3.32B$276.55M7 Day Performance-0.30%-0.66%-0.56%-0.93%1 Month Performance83.21%13.02%8.20%6.04%1 Year Performance86.92%19.45%75.60%40.02% 89BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89BIO2.8392 of 5 stars$14.79-0.1%$25.81+74.6%+90.0%$2.19BN/A-4.1040RVMDRevolution Medicines4.0825 of 5 stars$46.58-0.3%$74.64+60.2%-3.4%$8.73B$11.58M-10.35250MRUSMerus0.8923 of 5 stars$94.270.0%$93.12-1.2%+77.6%$7.13B$56.23M-17.1437RNAAvidity Biosciences1.9786 of 5 stars$46.18-1.7%$68.32+47.9%+5.1%$6.86B$10.90M-12.97190Positive NewsGRFSGrifols3.7847 of 5 stars$9.61-3.4%$10.30+7.2%+10.0%$6.84B$7.81B8.2123,822Analyst DowngradeCYTKCytokinetics3.6567 of 5 stars$60.64+6.4%$76.64+26.4%+8.6%$6.82B$18.47M-11.89250RYTMRhythm Pharmaceuticals3.3498 of 5 stars$97.86-1.2%$106.64+9.0%+102.3%$6.58B$130.13M-32.51140Positive NewsABVXAbivax2.8548 of 5 stars$86.67+3.3%$103.29+19.2%+904.5%$6.34BN/A0.0061Analyst ForecastGap UpHigh Trading VolumeCRSPCRISPR Therapeutics1.8372 of 5 stars$70.19+3.6%$71.50+1.9%+45.8%$6.16B$37.31M-12.93460Analyst ForecastNUVLNuvalent2.7678 of 5 stars$83.85-0.4%$118.89+41.8%-13.4%$6.07BN/A-17.1140AXSMAxsome Therapeutics4.6835 of 5 stars$119.94-0.3%$177.93+48.4%+38.4%$6.00B$385.69M-23.66380Analyst Revision Related Companies and Tools Related Companies Revolution Medicines Alternatives Merus Alternatives Avidity Biosciences Alternatives Grifols Alternatives Cytokinetics Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives CRISPR Therapeutics Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETNB) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89BIO Please log in to your account or sign up in order to add this asset to your watchlist. Share 89BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
